Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).

Technetium-99m, the most commonly used radionuclide in nuclear medicine, can be attached to biologically important molecules through a variety of chelating agents, the choice of which depends upon the imaging application. The prostate-specific membrane antigen (PSMA) is increasingly recognized as an important target for imaging and therapy of prostate cancer (PCa). Three different (99m)Tc-labeling methods were employed to investigate the effect of the chelator on the biodistribution and PCa tumor uptake profiles of 12 new urea-based PSMA-targeted radiotracers. This series includes hydrophilic ligands for radiolabeling with the [(99m)Tc(CO)3](+) core (L8-L10), traditional NxSy-based chelating agents with varying charge and polarity for the (99m)Tc-oxo core (L11-L18), and a (99m)Tc-organohydrazine-labeled radioligand (L19). (99m)Tc(I)-Tricarbonyl-labeled [(99m)Tc]L8 produced the highest PSMA+ PC3 PIP to PSMA- PC3 flu tumor ratios and demonstrated the lowest retention in normal tissues including kidney after 2 h. These results suggest that choice of chelator is an important pharmacokinetic consideration in the development of (99m)Tc-labeled radiopharmaceuticals targeting PSMA.

[1]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  W. Eckelman,et al.  Synthesis and SAR of ⁹⁹mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. , 2013, Bioorganic & medicinal chemistry letters.

[3]  Paul D Benny,et al.  PSMA‐targeted SPECT agents: Mode of binding effect on in vitro performance , 2013, The Prostate.

[4]  William C. Eckelman,et al.  First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[5]  A. Dash,et al.  Sustained Availability of 99mTc: Possible Paths Forward , 2013, The Journal of Nuclear Medicine.

[6]  George Sgouros,et al.  Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[7]  W. Eckelman,et al.  Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: Effects of chelate design on pharmacokinetics , 2012 .

[8]  J. Bryan,et al.  A phosphoramidate‐based prostate‐specific membrane antigen‐targeted SPECT agent , 2012, The Prostate.

[9]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[10]  Steve Y. Cho,et al.  GCPII imaging and cancer. , 2012, Current medicinal chemistry.

[11]  M. Pomper,et al.  Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. , 2011, Angewandte Chemie.

[12]  A. Pontecorvi,et al.  Biochemical Alterations in Semen of Varicocele Patients: A Review of the Literature , 2011, Advances in urology.

[13]  S. Tagawa,et al.  Prostate-Specific Membrane Antigen-Based Therapeutics , 2011, Advances in urology.

[14]  S. Hosseinimehr,et al.  Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties , 2011, The Journal of Nuclear Medicine.

[15]  Martin G Pomper,et al.  68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. , 2010, Journal of medicinal chemistry.

[16]  Martin G Pomper,et al.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. , 2009, Cancer research.

[17]  Fan Wang,et al.  2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. , 2009, Bioconjugate chemistry.

[18]  J. Konvalinka,et al.  Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III , 2009, The FEBS journal.

[19]  Philip S Low,et al.  Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. , 2009, Molecular pharmaceutics.

[20]  J. Zubieta,et al.  Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals. , 2009, Chemical communications.

[21]  Martin G Pomper,et al.  Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). , 2008, Journal of medicinal chemistry.

[22]  R. Schibli,et al.  "Click-to-chelate": in vitro and in vivo comparison of a 99mTc(CO)3-labeled N(tau)-histidine folate derivative with its isostructural, clicked 1,2,3-triazole analogue. , 2008, Bioconjugate chemistry.

[23]  J. Konvalinka,et al.  Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs , 2008, The Prostate.

[24]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[25]  J. Konvalinka,et al.  Biochemical characterization of human glutamate carboxypeptidase III , 2006, Journal of neurochemistry.

[26]  Shankar Vallabhajosula,et al.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Zubieta,et al.  A convenient synthesis, chemical characterization and reactivity of [Re(CO)3(H2O)3]Br: the crystal and molecular structure of [Re(CO)3(CH3CN)2Br] , 2004 .

[28]  J. Neale,et al.  NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR , 2004, Journal of neurochemistry.

[29]  J. Neale,et al.  The cloning and characterization of a second brain enzyme with NAAG peptidase activity , 2004, Journal of neurochemistry.

[30]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[31]  P. Blower,et al.  Solid-phase synthesis of peptide radiopharmaceuticals using Fmoc-N-epsilon-(hynic-Boc)-lysine, a technetium-binding amino acid: application to Tc-99m-labeled salmon calcitonin. , 2003, Journal of medicinal chemistry.

[32]  J. Reddy,et al.  Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. , 2002, Bioconjugate chemistry.

[33]  Luke G Green,et al.  A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. , 2002, Angewandte Chemie.

[34]  S. Gupta,et al.  A comparison in monkeys of (99m)Tc labeled to a peptide by 4 methods. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  V. Reuter,et al.  Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. , 2001, Urology.

[36]  Ning Liu,et al.  Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA , 2000, European Journal of Nuclear Medicine.

[37]  S. Mather,et al.  Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence , 1999, European Journal of Nuclear Medicine.

[38]  S. Jurisson,et al.  Potential technetium small molecule radiopharmaceuticals. , 1999, Chemical reviews.

[39]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[40]  S. Mather,et al.  Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide. , 1999, Bioconjugate chemistry.

[41]  J. Neefs,et al.  Isolation and Expression of Novel Human Glutamate Carboxypeptidases with N-Acetylated α-Linked Acidic Dipeptidase and Dipeptidyl Peptidase IV Activity* , 1999, The Journal of Biological Chemistry.

[42]  L. Luyt,et al.  An N2S2 bifunctional chelator for technetium-99m and rhenium: complexation, conjugation, and epimerization to a single isomer. , 1999, Bioconjugate chemistry.

[43]  M. Rajopadhye,et al.  Labeling cyclic glycoprotein IIb/IIIa receptor antagonists with 99mTc by the preformed chelate approach: effects of chelators on properties of [99mTc]chelator-peptide conjugates. , 1996, Bioconjugate chemistry.

[44]  L. E. Ross,et al.  Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. , 1996, Journal of medicinal chemistry.

[45]  A. Camerman,et al.  Technetium (V) and rhenium (V) complexes of 2,3-bis(mercaptoacetamido)propanoate. Chelate ring stereochemistry and influence on chemical and biological properties , 1990 .

[46]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[47]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.

[48]  R. Huisgen.  1,3-Dipolar Cycloadditions. Past and Future† , 1963 .

[49]  D. Hnatowich,et al.  Methods for MAG3 conjugation and 99mTc radiolabeling of biomolecules , 2006, Nature Protocols.

[50]  J. Zubieta,et al.  New directions in the coordination chemistry of 99mTc: a reflection on technetium core structures and a strategy for new chelate design. , 2005, Nuclear medicine and biology.

[51]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.